Overlap SJS-TEN in a kid and management protocols

SJS was most likely caused by infection not drugs in 1922 in New York City in two youngsters. It was described by the 2 pediatricians (A.M. Stevens and F.C. Johnson [1] in 1956. [1,2]. The term toxic Epidermal Necrolysis (TEN) is presented by A Lyell. Those lesions were assumed to be iatrogenic by an unknown toxin. Lang and Walker in 1956 represented TEN as a freelance entity [2]. The British Association of Dermatologists led a group of relevant experts to examine the evidence in developing guidelines to aid the diagnosis and management of SJS/TEN in children and young people [3]. High-risk drugs for the development of SJS-TEN include phenobarbital, phenytoin, carbamazepine, lamotrigine, nevirapine, nonsteroidal antiinfl ammatory drugs, allopurinol, cotrimoxazole, homeopathic medicines, and fl uconazole [4]. These three entities represent a spectrum of disease, with SJS the least and TEN the most severe, and the severity of SJS/TEN overlap syndrome in between [5]. The pathophysiology of overlap SJS TEN is not clear and different hypotheses were given for explanation. But the cause and effect of T cell infi ltrate yet to be explained until date. Programmed cell death of keratinocyte may be responsible for this. This is a paracrine interaction between Fas, a receptor (death) on Fas macromolecule and Keratinocytes or an autocrine one. NO-dependent fasL upregulation is seen in keratinocytes. It is driven by T-cell Interferon-gamma and TNF alfa mediated pathway. The treatment of SJS TEN Overlap is started with the immediate stoppage of the drug. Intravenous immunoglobulin, corticosteroids, cyclosporine, and symptomatic measurements are all essential for a smooth recovery from this life-threatening condition.


Introduction
SJS was most likely caused by infection not drugs in 1922 in New York City in two youngsters. It was described by the 2 pediatricians (A.M. Stevens and F.C. Johnson [1] in 1956. [1,2]. The term toxic Epidermal Necrolysis (TEN) is presented by A Lyell. Those lesions were assumed to be iatrogenic by an unknown toxin. Lang and Walker in 1956 represented TEN as a freelance entity [2]. The British Association of Dermatologists led a group of relevant experts to examine the evidence in developing guidelines to aid the diagnosis and management of SJS/TEN in children and young people [3]. High-risk drugs for the development of SJS-TEN include phenobarbital, phenytoin, carbamazepine, lamotrigine, nevirapine, nonsteroidal antiinfl ammatory drugs, allopurinol, cotrimoxazole, homeopathic medicines, and fl uconazole [4]. These three entities represent a spectrum of disease, with SJS the least and TEN the most severe, and the severity of SJS/TEN overlap syndrome in between [5]. The pathophysiology of overlap SJS TEN is not clear and different hypotheses were given for explanation. But the cause and effect of T cell infi ltrate yet to be explained until date. Programmed cell death of keratinocyte may be responsible for this. This is a paracrine interaction between Fas, a receptor (death) on Fas macromolecule and Keratinocytes or an autocrine one. NO-dependent fasL upregulation is seen in keratinocytes. It is driven by T-cell Interferon-gamma and TNF alfa mediated pathway. The treatment of SJS TEN Overlap is started with the immediate stoppage of the drug.
Intravenous immunoglobulin, corticosteroids, cyclosporine, and symptomatic measurements are all essential for a smooth recovery from this life-threatening condition.

Case report
The 4-year-old male child presented with fever, malaise, and pharyngitis uninterrupted for 3 days with mucosal and skin lesions. Cyclosporine was better in terms of improvement in decreasing mortality when compared to IVIG [6]. cal diagnosis was in favor of SJS-TEN OVERLAP. This is often characterized by detachment of skin between 10% and 30% of BSA. It was associated with erythroderma and purpuric macules. Some target-like rounded patches were also present.
Early withdrawal of the sinning drug amoxicillin was done and found to boost the general prognosis ( Figure 1).

Improvement in ocular outcome was visible if IVIG is given within half a dozen days of sickness onset. This was detected by
Kim et al. [7]. Oral or Injectable steroids had shown signifi cant improvement in ocular complications if started within 6 days of symptom onset and the same was also detected by Kim et al. [7]. SJS/TEN overlap is commonly exaggerated by medicines that have a brief plasma half-life [8].
Early administration of IVIG ideally within 48hrs of onset would improve life expectancy and decrease the chance of mortality and morbidity [7][8][9][10]. Ideally a total dose of 3g/kg of   IVIG is given for a period of 3-5 days [8]. oral or intravenous steroids would also improve ocular symptoms if started within 6 days of symptom onset [7]. However, neither IVIG nor steroids infl uenced the general death rate of SJS or TEN based on SCORTEN scoring [7] (Table 1). Cyclosporine was better in terms of improvement in decreasing mortality when compared to IVIG observed in a study [6].
A mixture of IVIG with systemic steroids was showing improvement and it was ascertained in a recently printed article. Cyclosporine at a dose of 3-6mg/kg dose for 7 days followed by a tapering course might be benefi cial. In a retrospective study [11], cyclosporine proved to be better in terms of improvement in death rate when compared to IVIG [11]. However, the results could be mixed up by the very fact that the group of patients who received cyclosporine were comparatively healthier [12]. Nasogastric feeding is usually needed. Oral hygiene is required to avoid superinfection [13].

Conclusion
Childhood overlap SJS TEN could be a sickness of vital mortality and long-run morbidity. Diagnosis and emergency referral became a live saving one. Cyclosporine was better in terms of improvement in decreasing mortality when compared to IVIG [6]. In remote areas, corticosteroids could have been an alternative to both cyclosporine and IVIG.